Antidiabetic Biosimilars Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 2,000.00$ 6,900.00

Antidiabetic Biosimilars Market: By Drug Class (Insulin, Biguanides, Sulfonyl Ureas, Thiazolidinediones, Di Peptidyl Peptidase (DPP)-IV Inhibitors, α-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others),By Disease Type (Type-I Diabetes, Type-II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

 

 

$ PRICE - $ 2,000.00$ 6,900.00
Clear selection
Clear
$ PRICE - $ 2,000.00$ 6,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules. Antidiabetics help diabetic people control their blood glucose levels. Biguanides, thiazolidinediones, DPP-IV inhibitors, -glucosidase inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists like exenatide are examples of antidiabetics. A biosimilar product is a biological product that has been approved by the FDA because it is very similar to an FDA-approved biological product called a reference product. To demonstrate that the biosimilar manufactured gives the same therapeutic benefit to patients as the reference medication, biosimilar manufacturers must generate data from lab testing and clinical testing.

Key Developments:

In May 2017, Sanofi received Committee for Medicinal Products for Human Use (CHMP) recommendation for approval of Insulin Lispro Biosimilar

Antidiabetic Biosimilars Market

MARKET SUMMARY
-
x%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– x%
  • Largest Market– Asia-Pacific
  • Fastest Growing Market– North America

Antidiabetic Biosimilars Market

  • The report on global antidiabetic biosimilars market gives historical, current and future market sizes (US$ Bn) based on drug type, disease type, distribution channel and region.
  • antidiabetic biosimilars market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Biocon
  • Merck Sharp & Dohme Corporation
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co.
  • Sanofi-aventis U.S. LLC
Antidiabetic Biosimilars Market

Drivers And Restraints

Drivers: Increase in the prevalence of diabetic patients
Patent expiries block buster drugs and promising product pipeline
Government initiations to control the diabetes

Restraints: High cost of R&D activities
Stringent regulatory policies
Complexity in development of biosimilars


North-America got significant share

Antidiabetic Biosimilars Market

Geographically radiotherapy market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to witness significant growth in the antidiabetic biosimilars market. Furthermore, Asia Pacific is expected to register a robust growth rate.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Antidiabetic Biosimilars Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

1. Executive Summary

2. Global Anti diabetic Biosimilars Market Introduction

2.1. Global Anti diabetic Biosimilars Market– Taxonomy

2.2. Global Anti diabetic Biosimilars Market–Definitions

2.2.1. Drug Class

2.2.2. Disease Type

2.2.3. Distribution Channel

3. Global Anti diabetic Biosimilars Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Anti diabetic Biosimilars Market Dynamic Factors – Impact Analysis

3.6. Global Anti diabetic Biosimilars Market– Competition Landscape

3.7. Epidemiology

4. Global Anti diabetic Biosimilars MarketAnalysis,2015 – 2019 and Forecast, 2020 – 2026

4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market OpportunityAnalysis

5. Global Anti diabetic Biosimilars Market, By Drug Class, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.1. Insulin

5.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Biguanides

5.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Sulfonyl Ureas

5.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

5.4. Thiazolidinediones

5.4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.4.3. Market Opportunity Analysis

5.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors

5.5.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.5.3. Market Opportunity Analysis

5.6. α-glucosidase Inhibitos

5.6.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.6.3. Market Opportunity Analysis

5.7. GLP-1 Agonists

5.7.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.7.3. Market Opportunity Analysis

5.8. Others

5.8.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.8.3. Market Opportunity Analysis

6. Global Anti diabetic Biosimilars Market Forecast, By Disease Type, 2015 – 2019 and Forecast, 2019 – 2026

6.1. Type-I Diabetes

6.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Type-II Diabetes

6.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

7. Global Anti diabetic Biosimilars Market Forecast, By Distribution Channel, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

7.1. Hospital Pharmacies

7.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Retail Pharmacies

7.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Online Pharmacies

7.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

8. Global Anti diabetic Biosimilars Market Forecast, By Region, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

8.1. North America

8.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

8.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

8.5.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.5.3. Market Opportunity Analysis

8.6. Global Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2020 – 2026

9. North America Anti diabetic Biosimilars Market Analysis,2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

9.1. Drug Class Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

9.1.1. Insulin

9.1.2. Biguanides

9.1.3. Sulfonyl Ureas

9.1.4. Thiazolidinediones

9.1.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors

9.1.6. α-glucosidase Inhibitos

9.1.7. GLP-1 Agonists

9.1.8. Others

9.2. Disease Type Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.2.1. Type-I Diabetes

9.2.2. Type-II Diabetes

9.3. Distribution Channel Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies

9.3.3. Online Pharmacies

9.4. Country Analysis 2016 and Forecast 2020 – 2026 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.4.1. U.S.

9.4.2. Canada

9.5. North America Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2020 – 2026

9.6. North America Anti diabetic Biosimilars Market Dynamics – Trends

10. Europe Anti diabetic Biosimilars Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

10.1. Drug Class Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

10.1.1. Insulin

10.1.2. Biguanides

10.1.3. Sulfonyl Ureas

10.1.4. Thiazolidinediones

10.1.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors

10.1.6. α-glucosidase Inhibitos

10.1.7. GLP-1 Agonists

10.1.8. Others

10.2. Disease Type Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Type-I Diabetes

10.2.2. Type-II Diabetes

10.3. Distribution Channel Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.3.1. Hospital Pharmacies

10.3.2. Retail Pharmacies

10.3.3. Online Pharmacies

10.4. Country Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.4.1. Germany

10.4.2. UK

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Poland

10.4.8. Rest of Europe

10.5. Europe Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2020 – 2026

10.6. Europe Anti diabetic Biosimilars Market Dynamics – Trends

11. Asia-Pacific Anti diabetic Biosimilars Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

11.1. Drug Class Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

11.1.1. Insulin

11.1.2. Biguanides

11.1.3. Sulfonyl Ureas

11.1.4. Thiazolidinediones

11.1.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors

11.1.6. α-glucosidase Inhibitos

11.1.7. GLP-1 Agonists

11.1.8. Others

11.2. Disease Type Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Type-I Diabetes

11.2.2. Type-II Diabetes

11.3. Distribution Channel Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Hospital Pharmacies

11.3.2. Retail Pharmacies

11.3.3. Online Pharmacies

11.4. Country Analysis2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. ASEAN

11.4.5. Australia & New Zealand

11.4.6. Rest of Asia-Pacific

11.5. Asia-Pacific Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2020 – 2026

11.6. Asia-Pacific Anti diabetic Biosimilars Market Dynamics – Trends

12. Latin America Anti diabetic Biosimilars Market Analysis, 2012 – 2012 – 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

12.1. Drug Class Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

12.1.1. Insulin

12.1.2. Biguanides

12.1.3. Sulfonyl Ureas

12.1.4. Thiazolidinediones

12.1.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors

12.1.6. α-glucosidase Inhibitos

12.1.7. GLP-1 Agonists

12.1.8. Others

12.2. Disease Type Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Type-I Diabetes

12.2.2. Type-II Diabetes

12.3. Distribution Channel Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Hospital Pharmacies

12.3.2. Retail Pharmacies

12.3.3. Online Pharmacies

12.4. Country Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Argentina

12.4.4. Venezuela

12.4.5. Rest of Latin America

12.5. Latin America Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2020 – 2026

12.6. Latin America Anti diabetic Biosimilars Market Dynamics – Trends

13. Middle East and Africa Anti diabetic Biosimilars Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

13.1. Drug Class Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

13.1.1. Insulin

13.1.2. Biguanides

13.1.3. Sulfonyl Ureas

13.1.4. Thiazolidinediones

13.1.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors

13.1.6. α-glucosidase Inhibitos

13.1.7. GLP-1 Agonists

13.1.8. Others

13.2. Disease Type Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.2.1. Type-I Diabetes

13.2.2. Type-II Diabetes

13.3. Distribution Channel Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.3.1. Hospital Pharmacies

13.3.2. Retail Pharmacies

13.3.3. Online Pharmacies

13.4. Country Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

13.4.1. Gulf Cooperation Council (GCC) Countries

13.4.2. Israel

13.4.3. South Africa

13.4.4. Rest of MEA

13.5. MEA Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2020 – 2026

13.6. MEA Anti diabetic Biosimilars Market Dynamics – Trends

14. Competition Landscape

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. Biocon (India)

14.2.2. Merck Sharp & Dohme Corporation (U.S.)

14.2.3. Boehringer Ingelheim GmbH (Germany)

14.2.4. Eli Lilly & Co. (U.S.)

14.2.5. Sanofi-aventis U.S. LLC (U.S.)

14.2.6. Samsung Bioepis (Samsung BioLogics) (South Korea)

14.2.7. Mylan N.V. (U.S.)

14.2.8. Wockhardt (India)

15. Research Methodology

16. Key Assumptions and Acronyms


Report

Company Profile

  • Biocon (India)
  • Merck Sharp & Dohme Corporation (U.S.)
  • Boehringer Ingelheim GmbH (Germany)
  • Eli Lilly & Co. (U.S.)
  • Sanofi-aventis U.S. LLC (U.S.)
  • Samsung Bioepis (Samsung BioLogics) (South Korea)
  • Mylan N.V. (U.S.)
  • Wockhardt (India)

Description

Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules. Antidiabetics help diabetic people control their blood glucose levels. Biguanides, thiazolidinediones, DPP-IV inhibitors, -glucosidase inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists like exenatide are examples of antidiabetics. A biosimilar product is a biological product that has been approved by the FDA because it is very similar to an FDA-approved biological product called a reference product. To demonstrate that the biosimilar manufactured gives the same therapeutic benefit to patients as the reference medication, biosimilar manufacturers must generate data from lab testing and clinical testing.

Key Developments:

In May 2017, Sanofi received Committee for Medicinal Products for Human Use (CHMP) recommendation for approval of Insulin Lispro Biosimilar

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX